Federal prisons must stock naloxone to prevent overdose deaths

What it does

This bill requires the Federal Bureau of Prisons to stock naloxone (an opioid overdose reversal drug) at every federal prison in multiple accessible locations—medical units, staff areas, visiting rooms, housing units, dining halls, and common areas. It mandates annual training for staff and incarcerated people on how to recognize and treat overdoses, requires documentation of every naloxone use, shields incarcerated people from liability if they administer it in good faith, and directs the BOP to report annually to Congress on compliance, overdose incidents, and expired supplies. The bill authorizes $6 million for 2026 and $2 million annually for 2027–2028.

Why we flagged it

The bill is a straightforward operational directive to a federal agency (BOP) to implement a specific public health intervention (naloxone availability and training) in federal prisons. It is not a tax measure, appropriation, or regulatory carve-out—it is a mandate backed by modest appropriations.

What the text implies

• Naloxone availability in prisons may reduce overdose-related deaths and emergency medical costs, but the bill does not address underlying opioid supply or addiction treatment capacity—it is a harm-reduction measure, not a cure.
• The liability shield for incarcerated people administering naloxone in good faith is protective but may create ambiguity about what constitutes 'good faith' in a prison setting, potentially leading to disputes over whether an administration was justified.

The full analysis lists 4 implications of this text.

Who stands to gain

pharmaceutical manufacturers of naloxone (Amphastar, Kaléo, Adapt Pharma/Purdue, others); medical suppliers and distributors of naloxone kits; training and consulting firms contracted by BOP